Leukemia therapy and early death. A form of transformation with large hairy cells has also been described in HCL.
Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion TO 
THE EDITOR
The spectrum of therapeutic options against B cell lymphoma has been recently expanded by the availability of rituximab, a chimeric antibody directed against the CD20 antigen that is expressed by more than 95% B cell non-Hodgkin lymphomas. [1] [2] [3] [4] [5] The effector mechanism of rituximab includes complement-mediated cell lysis, antibodydependent cellular cytotoxicity and triggering of apoptosis. The wide acceptance of rituximab has been facilitated by the favorable toxicity profile of the drug. Side-effects are restricted to first infusion-related fever, chills, rigors, flushing, nausea and vomiting, which are usually self-limited and generally subside with temporary interruption of rituximab infusion. Recently, however, a severe rituximab-induced toxic syndrome has been reported in patients with massive peripheral blood neoplastic invasion. [6] [7] [8] This syndrome, which occurs early during drug infusion, is heralded by fever, chills, and thrombocytopenia. It is caused by peripheral blood cell lysis attended by a cytokine release syndrome, mainly attributable to increased levels of IL-6 and TNF␣. [6] [7] [8] The risk correlates with the neoplastic burden of lymphoid cells in peripheral blood, and it is minimal when the peripheral lymphocyte count is less than 40 × 10 9 /l. 6 To our knowledge, this syndrome has not been reported in patients without leukemic invasion.
Here, we report a case of severe toxic syndrome after rituximab infusion in a patient without leukemic invasion but with massive splenomegaly. A 60-year-old female with heavily pretreated and refractory lymphoplasmacytoid lymphoma presented with bone marrow involvement (60% neoplastic cells) and marked splenomegaly (23 cm diameter). The leukocyte count was 1.1 × 10 9 /l, the platelet count 86 × 10 9 /l, hemoglobin was 9.7 g/dl. The patient, who had denied permission for further chemotherapy and splenic radiation after the last disease relapse, was offered a trial of rituximab. After intravenous hydration and premedication with chlorphenamine (10 mg) and dexamethasone (8 mg), rituximab infusion (375 mg/m 2 ) was started at 50 mg/h and then increased by 50 mg/h every 30 min to a maximum of 400 mg/h. The patient remained asymptomatic and was discharged from hospital 1 h after the end of treatment. In the following hours the patient started to complain of malaise, chills, fever (38.5°C) and persistent epistaxis ( Table 1 ). The blood cell count performed 5 h after ending rituximab infusion revealed severe thrombocytopenia (7 × 10 9 /l; grade 4 according to the NCI common toxicity criteria) with no change in white blood cells or hemoglobin. A two-fold increase in AST, ALT and LDH was also measured. Coagulation parameters (INR, aPTT, fibrinogen and D-dimer levels) and serum electrolytes were within the normal range. Blood pressure was within the patient's normal range. Because of the persistency of epistaxis, the patient was transfused with two platelet units, after which the platelet count increased to 28 × 10 9 /l. She also received prednisolone 100 mg i.v. Platelet counts were then closely monitored every 6-12 h ( Figure 1 ) and returned to baseline levels (87 × 10 9 /l) after 96 h. Malaise, chills and fever regressed within 24 h, whereas epistaxis persisted for approximately 60 h. Liver enzymes and LDH returned to baseline lev- Table 1 Toxic effects of rituximab in the patient described in this case report (according to NCI Common Toxicity Criteria version 2.0)
Adverse events NCI grade 
Figure 1
Monitoring of platelet count during 96 h after the onset of the first rituximab infusion. At baseline, the patient's platelet count was 86 × 10 9 /l. Rituximab infusion was started at time 0, lasted approximately 3 h and was followed by a drastic fall in platelet count by the 6 h. The patient received a platelet transfusion and prednisolone 100 mg i.v. (indicated by an arrow in the figure), after which the platelet count was 28 × 10 6 /l. Subsequently, the platelet count rose spontaneously and returned to baseline levels by 96 h. els after 96 h. Ultrasonogram investigation of the spleen did not reveal significant size variation compared to baseline. Ten days after the first rituximab infusion, the patient received rituximab in a fractioned infusion schedule:
6 on day 1, 50 mg rituximab was administered over 5-7 h; on day 2, 100 mg over the same period of time; on day 3, the remainder of the 375 mg/m 2 dose. No changes in platelet cell count or LDH were observed during the 3 days of therapy, whereas liver enzymes displayed a mild increase.
The implications of this case report are three-fold. Firstly, rituximab infusion may be associated with a severe toxic syndrome, overall compatible with the previously described cytokine release syndrome, despite the absence of peripheral blood invasion by the tumor. Secondly, monitoring of platelet counts should be mandatory in all patients at risk for rituximab-induced thrombocytopenia, including patients with massively invaded spleens. Thirdly, fractioned infusion schedule may offer advantages in patients at risk of cytokine release syndrome. It is conceivable that, in our patient, tumor lysis in the context of massive splenomegaly may have sustained the toxic syndrome, which is otherwise caused by leukemic cell lysis. [6] [7] [8] As in leukemic patients the severity of the cytokine release syndrome correlates with the degree of peripheral blood invasion, [6] [7] [8] future studies need to address whether the toxic effects of rituximab in non-leukemic patients are directly related to the size of organomegaly.
Remission of severe cold agglutinin disease after Rituximab therapy
TO THE EDITOR Rituximab (Mabthera; Roche, Brussels, Belgium) has demonstrated activity in the treatment of non-Hodgkin's lymphoma (NHL) of B cell origin. 1 This antibody, which binds specifically to the CD20 antigen, a pan B cell marker, can deplete B cells through complement-and antibody-dependent cellular cytotoxicity. Rituximab is presumably active in Waldenströ m's macroglobulinemia (WM) because of the elimination of either CD20
+ clonotypic precursor B cells, or CD20 + plasma cells, which have both been detected in most WM patients. 2 The same rationale could apply to other immunoglobulin-mediated diseases of B lymphocytes, such as cold agglutinin disease (CAD) or cryoglobulinemia, which could also theoretically benefit from CD20 
